Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Sevredol tablets 50mg

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Morphine sulfate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Morphine sulfate
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for This medicine has been prescribed for you for the relief of severe pain. It contains morphine, which belongs to a class of medicines called opioids, which are 'pain relievers'. The medicine has been prescribed for you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your doctor should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.

What you need to know before you take it

e Sevredol tablets Do not take Sevredol tablets if:

  • you are allergic to morphine or any of the other ingredients of the tablets (see section 6);
  • you have breathing problems, such as obstructive airways disease, respiratory depression or severe asthma. Your doctor will have told you if you have these conditions. Symptoms may include breathlessness, coughing or breathing more slowly or weakly than expected;
  • you have a condition where the small bowel (part of your gut) does not work properly (paralytic ileus), your stomach empties more slowly than it should (delayed gastric emptying) or you have severe pain in your abdomen;
  • you have a head injury that causes a severe headache or makes you feel sick. This is because the tablets may make these symptoms worse or hide the extent of the head injury;
  • you have recent onset liver disease;
  • you are taking a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromine, phenelzine, isocarboxazid, moclobemide and linezolid), or you have taken this type of medicine in the last two weeks;
  • the patient is under three years of age.

Tolerance, dependence, and addiction This medicine contains morphine which is an opioid medicine. Repeated use of opioids can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Sevredol tablets can also lead to dependence, abuse, and addiction, which may result in lifethreatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to Sevredol tablets if:

  • You or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction").
  • You are a smoker.
  • You have ever had problems with your mood (depression, anxiety, or a personality disorder) or have been treated by a psychiatrist for other mental illnesses. If you notice any of the following signs whilst taking Sevredol tablets, it could be a sign that you have become dependent or addicted:
  • You need to take the medicine for longer than advised by your doctor
  • You need to take more than the recommended dose
  • You are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'
  • You have made repeated, unsuccessful attempts to quit or control the use of the medicine
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects') If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (See section 3, If you stop taking Sevredol tablets). Warnings and precautions Tell your doctor or pharmacist before taking these tablets if you experience any of the following symptoms while taking Sevredol tablets:
  • are or have ever been addicted to opioids, alcohol, prescription medicines, or illegal drugs;
  • have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating when you have stopped taking alcohol or drugs;
  • feel you need to take more Sevredol tablets to get the same level of pain relief, this may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your doctor who will discuss your treatment and may change your dose or switch you to an alternative pain reliever;
  • have breathing problems, such as impaired lung function or severe bronchial asthma. Your doctor will have told you if you have these conditions. Symptoms may include breathlessness and coughing;
  • have a severe heart problem after long-term lung disease (severe cor pulmonale);
  • have a head injury or severe headache or feel sick as this may indicate that the pressure in your skull is increased;
  • have low blood pressure;
  • have an under-active thyroid gland (hypothyroidism);

• • • • • • • • •

have kidney or liver problems; suffer from, or have ever suffered from, epilepsy, seizures, fits or convulsions; have inflammation of the pancreas or have problems with your gall bladder due to gall stones; have an inflammatory bowel disorder; you suffer from constipation; have prostate problems; experience weakness, fatigue, lack of appetite, nausea, vomiting or low blood pressure. This may be a symptom of the adrenals producing too little of the hormone cortisol, and you may need to take a hormone supplement; have loss of libido, impotence or your menstrual cycle stops. This may be because of decreased sex hormone production; have sickle cell disease.

If you are going to have an operation, please tell the doctor at the hospital that you are taking these tablets. Contact your doctor if you experience severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever as this could be symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system. Taking this medicine regularly, particularly for a long time, can lead to addiction. Your doctor should have explained how long you will be using it for and when it is appropriate to stop, how to do this safely. Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your doctor about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your doctor will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. Acute generalized exanthematous pustulosis (AGEP) has been reported in association with Sevredol tablets treatment. Symptoms usually occur within the first 10 days of treatment. Tell your doctor if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking Sevredol tablets or other opioids. Stop using Sevredol tablets and seek medical attention immediately, if you notice any of the following symptoms: blistering, widespread scaly skin or pusfilled spots together with fever. Sleep-related breathing disorders Sevredol tablets can cause breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or

excessive drowsiness during the day. If you or another person observes these symptoms contact your doctor. A dose reduction may be considered by your doctor. You may experience hormonal changes while taking these tablets. Your doctor may want to monitor these changes. Other medicines and Sevredol tablets Concomitant use of Sevredol and sedative medicines, such as benzodiazepines or related drugs, increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However, if your doctor does prescribe Sevredol together with sedative medicines, the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. If you take these tablets with some other medicines, the effect of the tablets or the other medicine may be changed. Sevredol tablets must not be used together with a monoamine oxidase inhibitor, or if you have taken this type of medicine in the last two weeks (see section 2 'Do not take…'). Tell your doctor or pharmacist if you are taking any of the medicines mentioned below. A large number of drugs can interact with morphine sulfate tablets which can significantly alter their effects. These drugs include:

  • medicines to help you sleep (for example benzodiazepines, tranquillisers, hypnotics or sedatives);
  • medicines to treat psychiatric or mental disorders (such as phenothiazines);
  • muscle relaxants;
  • medicines to treat high blood pressure;
  • cimetidine to treat stomach ulcers, indigestion or heartburn;
  • certain types of medicines to stop you feeling or being sick;
  • medicines used to prevent or relieve the symptoms of an allergy (antihistamines);
  • other strong analgesics or 'painkillers' (such as buprenorphine, nalbuphine or pentazocine);
  • rifampicin to treat tuberculosis;
  • ritonavir to treat HIV;
  • medicines to treat Parkinson's disease;
  • gabapentin or pregabalin to treat epilepsy and pain due to nerve problems (neuropathic pain);
  • some medicines used to treat blood clots (e.g. clopidogrel, prasugrel, ticagrelor) may have delayed and decreased effect when taken together with morphine. Also tell your doctor if you have recently been given a general anaesthetic. Sevredol tablets and alcohol Drinking alcohol during your treatment with these tablets may make you sleepy. If you are affected, you should avoid drinking alcohol.

Pregnancy and breastfeeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not take Sevredol tablets if you are pregnant or think you might be pregnant unless you have discussed this with your doctor and the benefits of treatment are considered to outweigh the potential harm to the baby. If you take Sevredol tablets during pregnancy your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Withdrawal (abstinence) symptoms in babies born to mothers who have used Sevredol tablets in pregnancy may include high-pitched crying, irritability and restlessness, shaking (tremor), feeding difficulties and sweating. Do not take Sevredol tablets while you are breastfeeding as morphine passes into breast milk and will affect your baby. Driving and using machines These tablets may cause a number of side effects such as drowsiness which could affect your ability to drive or use machinery (see section 4 for a full list of side effects). These are usually most noticeable when you first start taking the tablets, or when changing to a higher dose. If you are affected, you should not drive or use machinery. • • •

Do not drive, while taking this medicine, until you know how it affects you. It is an offence to drive if this medicine affects your ability to drive. However, you would not be committing an offence if: o The medicine has been prescribed to treat a medical or dental problem and o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and o It was not affecting your ability to drive safely.

Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. Sevredol tablets contain lactose and sunset yellow (E110) These tablets contain lactose which is a form of sugar. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking these tablets. The 20 mg tablets contain sunset yellow (E110) which may cause allergic reactions.

How to take it

Sevredol tablets Always take the tablets exactly as your doctor has told you. The label on your medicine will tell you how many tablets to take and how often. Check with your doctor or pharmacist if you are not sure. Before starting treatment, and regularly during treatment, your doctor will discuss with you what you may expect from using Sevredol tablets, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also, If you stop taking Sevredol tablets in this section). They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Swallow your tablets whole with a glass of water.

You must only take the tablets by mouth. The tablets should never be crushed and injected as this may lead to serious side effects, which may be fatal. Adults The usual starting dose is one tablet every 4 hours. Your doctor will decide how many tablets you should take. Children Only the 10 mg and 20 mg strength tablets are suitable for children. Children should not be given the 50 mg tablets. Children 3 to 5 years of age The usual dose is 5 mg every four hours. Children 6 to 12 years of age The usual dose is 5 – 10 mg every four hours. If you find that you are still in pain whilst taking these tablets, discuss this with your doctor. Do not exceed the dose recommended by your doctor. You should check with your doctor or pharmacist if you are not sure. If you take more Sevredol tablets than you should or if someone accidentally swallows your tablets Call your doctor or hospital straight away as you may need emergency treatment in a hospital. People who have taken an overdose may feel very sleepy, sick, dizzy or get pneumonia from inhaling vomit or foreign matter (symptoms may include breathlessness, cough and fever). People who have taken an overdose may also have breathing difficulties leading to unconsciousness or even death. An overdose may result in: • A brain disorder (known as toxic leukoencephalopathy) When seeking medical attention make sure that you take this leaflet and any remaining tablets with you to show to the doctor. If you forget to take Sevredol tablets If you miss a dose you should take it as soon as you remember and then carry on as before. Do not take two doses within 4 hours. Do not take a double dose to make up for a forgotten tablet. If you stop taking Sevredol tablets Do not suddenly stop taking this medicine. If you want to stop taking this medicine discuss this with your doctor first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Possible side effects

Like all medicines, these tablets can cause side effects, although not everybody gets them.

Stop using Sevredol tablets and seek medical attention immediately if you notice any of the following symptoms:  Sudden wheeziness, difficulties in breathing, dizziness, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. These may be signs of a severe allergic reaction.  Severe skin reaction with blistering, widespread scaly skin, pus-filled spots together with fever. This could be a condition called Acute Generalized Exanthematous Pustulosis (AGEP).  You begin to breathe more slowly or weakly than expected. This could be a sign of a condition called respiratory depression. The following other side effects may also occur: Very common (may affect more than 1 in 10 people)

  • Feeling sick.
  • Constipation (your doctor can prescribe a laxative to overcome this problem). Common (may affect up to 1 in 10 people)
  • Loss of appetite, dry mouth, abdominal pain or discomfort.
  • Vomiting (being sick). (This should normally wear off after a few days. However, your doctor can prescribe an anti-vomiting medicine if it continues to be a problem).
  • Drowsiness (this is most likely when you start taking your tablets or when your dose is increased but should wear off after a few days).
  • Dizziness, headache, confusion, difficulty in sleeping.
  • A feeling of unusual weakness.
  • Generally feeling unwell, tiredness.
  • Involuntary muscle contractions.
  • Rash or itchy skin.
  • Sweating. Uncommon (may affect up to 1 in 100 people)
  • Withdrawal symptoms (see section 'Drug Withdrawal').
  • Indigestion, changes in taste.
  • A condition where the bowel does not work properly (ileus).
  • Vertigo, (a feeling of dizziness or 'spinning'), fainting, seizures, fits or convulsions.
  • Agitation, mood changes, hallucinations, a feeling of extreme happiness.
  • Unusual muscle stiffness.
  • Difficulty in breathing (possibly due to fluid on the lungs) or wheezing.
  • Tingling or numbness.
  • Difficulty in passing urine.
  • Low blood pressure, facial flushing (redness of the face).
  • Feeling your heart beat (palpitations).
  • Swelling of the hands, ankles or feet.
  • A raised, itchy rash (hives).
  • A worsening in liver function tests (seen in a blood test).
  • Blurred vision.
  • Muscle spasms. Frequency not known (Frequency cannot be estimated from the available data):
  • Sleep apnoea (breathing pauses during sleep)
  • Unpleasant or uncomfortable mood, abnormal thoughts.

• • • • • • • • • •

An increased sensitivity to pain. Reduction in size of the pupils in the eye. A fast or slow heartbeat. High blood pressure. Decreased cough reflex. Symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system, e.g. severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever. Severe pain in the lower abdomen or bladder than may come and go. Absence of menstrual periods, decreased sexual drive, impotence. Withdrawal symptoms in babies born to mothers who have used Sevredol tablets in pregnancy (See section 2 "Pregnancy, breastfeeding and fertility"). Dependence and addiction (see section 'How do I know if I am addicted?').

Drug withdrawal When you stop taking Sevredol tablets you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. How do I know if I am addicted? If you notice any of the following signs whilst taking Sevredol tablets it could be a sign that you have become addicted.

  • You need to take the medicine for longer than advised by your prescriber;
  • You feel you need to use more than the recommended dose;
  • You are using the medicine for reasons other than prescribed;
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again. If you notice any of these signs it is important you talk to your doctor. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

How to store it

Sevredol tablets Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month. Do not store your tablets above 30°C. Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

Contents of the pack and other information

What Sevredol tablets contain The active ingredient is morphine sulfate. Each tablet contains 10 mg, 20 mg or 50 mg of morphine sulfate. The other ingredients are:

  • Lactose
  • Pregelatinised maize starch
  • Povidone
  • Magnesium stearate
  • Talc
  • Macrogol
  • Hypromellose (E464) (10 mg and 50 mg tablets only)
  • Titanium dioxide (E171)
  • Polyvinyl alcohol (E1203) (20 mg tablet only) The tablets also contain the following colourants: 10 mg – Brilliant blue (E133) 20 mg – Erythrosine (E127) and sunset yellow (E110) 50 mg – Quinoline yellow (E104), indigo carmine (E132) and iron oxide (E172) What Sevredol tablets look like and the contents of the pack The tablets have a score line on one side. 'IR' and the strength (e.g. 10, 20 etc) are on either side of the score line. The tablets are coloured as follows: 10 mg – blue, 20 mg – pink, 50 mg – pale green. In each box there are 56 tablets. Marketing Authorisation Holder Napp Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW, UK. Manufacturer Bard Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW, UK. This leaflet is also available in large print, Braille or as an audio CD. To request a copy, please call the RNIB Medicine Information line (free of charge) on: 0800 198 5000 You will need to give details of the product name and reference number. These are as follows: Product name: Sevredol tablets Reference number: 16950/0063 This leaflet was last revised in July 2024. ® Sevredol, NAPP and the NAPP logo are registered trade marks. © 2010 – 2024 Napp Pharmaceuticals Limited.

Frequently asked questions about Sevredol tablets 50mg

How do I take Sevredol tablets 50mg?

Sevredol tablets 50mg comes as tablet containing 50mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Sevredol tablets 50mg?

The active substance in Sevredol tablets 50mg is morphine sulfate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Sevredol tablets 50mg, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Sevredol tablets 50mg without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Morphine sulfate (45 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

SEVREDOL tablets 50 mg are indicated for the relief of severe pain.

4.2. Posology and method of administration

Posology

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with morphine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Adults and children over 12 years.

The dosage of Sevredol tablets is dependent on the severity of pain and the patient's previous history of analgesic requirements. One tablet to be taken every four hours or as directed by a physician. Increasing severity of pain or tolerance to morphine will require increased dosage of Sevredol tablets using 10 mg, 20 mg or 50 mg alone or in combination to achieve the desired relief.

Patients receiving Sevredol tablets in place of parenteral morphine should be given a sufficiently increased dosage to compensate for any reduction in analgesic effects associated with oral administration. Usually such increased requirement is of the order of 100%. In such patients, individual dose adjustments are required.

Elderly

A reduction in adult dosage may be advisable.

Paediatric population

Sevredol tablets 50 mg are not recommended for children.

Route of administration

Oral.

Discontinuation of therapy

An abstinence syndrome may be precipitated if opioid administration is suddenly discontinued. Therefore, the dose should be gradually reduced prior to discontinuation.

4.3. Contraindications

Morphine products are contraindicated in patients with:

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

• Severe chronic obstructive pulmonary disease

• Severe bronchial asthma

• Severe respiratory depression with hypoxia and/or hypercapnia

• Paralytic ileus

• Acute abdomen

• Head injury

• Delayed gastric emptying

• Known morphine sensitivity

• Acute hepatic disease

• Concurrent administration of mono-amine oxidase inhibitors or within two weeks of discontinuation of their use.

Not recommended during pregnancy.

Not recommended for children below 3 years of age.

4.4. Special warnings and precautions for use

Sevredol tablets should be administered in caution in patients with:

• Impaired respiratory function

• Respiratory depression (see below)

• Severe cor pulmonale

• Sleep apnoea

• CNS depressant co-administration (see below and section 4.5)

• Acute alcoholism

• Delirium tremens

• Head injury, intracranial lesions or increased intracranial pressure, reduced level of consciousness of uncertain origin.

• Hypotension with hypovolaemia

• Hypothyroidism,

• Adrenocortical insufficiency

• Convulsive disorders

• Biliary tract disorders

• Pancreatitis

• Prostatic hypertrophy

• Inflammatory bowel disorders

• Severely impaired renal function

• Severely impaired hepatic function

• Constipation

As with all narcotics a reduction in dosage may be advisable in the elderly.

Sevredol tablets should not be used where there is a possibility of paralytic ileus occurring. Should paralytic ileus be suspected or occur during use, Sevredol tablets should be discontinued immediately.

Respiratory Depression

The major risk of opioid excess is respiratory depression.

Opioids may cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use may increase the risk of CSA in a dose-dependent manner in some patients. Opioids may also cause worsening of pre-existing sleep apnoea (see section 4.8). In patients who present with CSA, consider decreasing the total opioid dosage.

Morphine may lower the seizure threshold in patients with a history of epilepsy.

Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs

Concomitant use of Sevredol tablets and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible.

If a decision is made to prescribe Sevredol tablets concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible (see also general dose recommendation in section 4.2).

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Acute chest syndrome (ACS) in patients with sickle cell disease (SCD) Due to a possible association between ACS and morphine use in SCD patients treated with morphine during a vaso-occlusive crisis, close monitoring for ACS symptoms is warranted.

Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Patients about to undergo additional pain relieving procedures (e.g. surgery, plexus blockade) should not receive Sevredol tablets for 4 hours prior to the intervention. If further treatment with Sevredol tablets is indicated then the dosage should be adjusted to new post-operative requirements. Sevredol tablets should be used with caution pre-operatively and within the first 24 hours post-operatively. Sevredol tablets should also be used with caution following abdominal surgery as morphine impairs intestinal motility and should not be used until the physician is assured of normal bowel function.

Drug dependence, tolerance and potential for abuse

For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g. major depression).

Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.

A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained online, and past and present medical and psychiatric conditions.

Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.

Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed and do not give this medicine to anyone else.

Patients should be closely monitored for signs of misuse, abuse or addiction.

The clinical need for analgesic treatment should be reviewed regularly.

Biliary tract disorders

Morphine can cause an increase in intrabiliary pressure and spasm as a result of its effects on the sphincter of Oddi; therefore, patients with diseases of the biliary tract should be monitored for worsening of symptoms while administering morphine.

Drug withdrawal syndrome

Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with morphine.

Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.

The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy there is a risk that their newborn infants will experience neonatal withdrawal syndrome.

Hyperalgesia

Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.

Opioid analgesics may cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of adrenal insufficiency may include e.g. nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, or low blood pressure.

Some changes that can be seen with long-term use of opioid analgesics include an increase in serum prolactin, and decreases in plasma cortisol, oestrogen and testosterone in association with inappropriately low or normal ACTH, LH or FSH levels. Clinical symptoms include decreased libido, impotence or amenorrhea which may be manifested from these hormonal changes.

Plasma concentrations of morphine may be reduced by rifampicin. The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin.

Oral P2Y12 inhibitor antiplatelet therapy

Within the first day of concomitant P2Y12 inhibitor and morphine treatment, reduced efficacy of P2Y12 inhibitor treatment has been observed (see section 4.5)

Abuse of oral dosage forms by parenteral administration can be expected to result in serious adverse events, which may be fatal.

4.5. Interaction with other medicinal products and other forms of interaction

The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dosage and duration of concomitant use should be limited (see section 4.4).

Drugs which depress the CNS include, but are not limited to: other opioids, anxiolytics, sedatives and hypnotics (including benzodiazepines), antiepileptics (including gabapentinoids, e.g., pregabalin), general anaesthetics (including barbiturates), antipsychotics (including phenothiazines), antidepressants, muscle relaxants, antihypertensives, centrally acting antiemetics and alcohol.

In a study involving healthy volunteers (N=12), when a 60-mg controlledrelease morphine capsule was administered 2 hours prior to a 600-mg gabapentin capsule, mean gabapentin AUC increase by 44% compared to gabapentin administered without morphine. Therefore, patients should be carefully observed for signs of CNS depression, such as somnolence, and the dose of gabapentin or morphine should be reduced appropriately.

Mixed agonist/antagonist opioid analgesics (e.g. buprenorphine, nalbuphine, pentazocine) should not be administered to a patient who has received a course of therapy with a pure opioid agonist analgesic.

Medicinal products that block the action of acetylcholine, for example antihistamines, anti-parkinsons and anti-emetics, may interact with morphine to potentiate the anticholinergic adverse effects.

Cimetidine inhibits the metabolism of morphine.

Monoamine oxidase inhibitors are known to interact with narcotic analgesics producing CNS excitation or depression with hyper- or hypotensive crisis. Morphine should not be co-administered with monoamine oxidase inhibitors or within two weeks of such therapy.

Plasma concentrations of morphine may be reduced by rifampicin (see section 4.4).

A delayed and decreased exposure to oral P2Y12 inhibitor antiplatelet therapy has been observed in patients with acute coronary syndrome treated with morphine. This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced P2Y12 inhibitor efficacy in patients coadministered morphine and a P2Y12 inhibitor (see section 4.4). In patients with acute coronary syndrome, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.

Although there are no pharmacokinetic data available for concomitant use of ritonavir with morphine, ritonavir induces the hepatic enzymes responsible for the glucuronidation of morphine, and may possibly decrease plasma concentrations of morphine.

4.6. Fertility, pregnancy and lactation

Pregnancy

Sevredol tablets are not recommended during pregnancy and labour. Regular use in pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate. If opioid use is required for a prolonged period in pregnant women, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.

Breastfeeding

Administration to nursing women is not recommended as morphine is secreted in breast milk and may cause respiratory depression in the infant.

Fertility

Animal studies have shown that morphine may reduce fertility (see 5.3 Preclinical safety data).

4.7. Effects on ability to drive and use machines

Treatment with Sevredol tablets may cause sedation and it is not recommended that patients drive or use machines if they experience drowsiness.

This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

• The medicine is likely to affect your ability to drive.

• Do not drive until you know how the medicine affects you.

• It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence').

• This defence applies when:

• The medicine has been prescribed to treat a medical or dental problem; and

• You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.

• Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected).”

Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law

4.8. Undesirable effects

In normal doses, the commonest side effects of morphine are nausea, vomiting, constipation and drowsiness. With chronic therapy, nausea and vomiting are unusual with Sevredol tablets but should they occur the tablets can be readily combined with an anti-emetic if required. Constipation may be treated with appropriate laxatives.

The following frequencies are the basis for assessing undesirable effects: Very common (≥1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000); Not known (cannot be estimated from the available data).

Very Common

Common

Uncommon

Not known

Immune system disorders

Hypersensitivity

Anaphylactic reaction

Anaphylactoid reaction

Psychiatric disorders

Confusion

Insomnia

Agitation

Euphoria

Hallucinations

Mood altered

Drug dependence (see section 4.4)

Dysphoria Thinking disturbances

Nervous system disorders

Dizziness

Headache

Hyperhidrosis

Involuntary muscle contractions

Somnolence

Convulsions

Hypertonia

Myoclonus

Paraesthesia

Syncope

Allodynia

Hyperalgesia (see section 4.4)

Sleep apnoea syndrome

Eye disorders

Visual impairment

Miosis

Ear and labyrinth disorders

Vertigo

Cardiac disorders

Palpitations

Bradycardia

Tachycardia

Vascular disorders

Facial flushing

Hypotension

Hypertension

Respiratory thoracic and mediastinal disorders

Bronchospasm

Pulmonary oedema

Respiratory depression

Cough decreased

Gastrointestinal disorders

Constipation

Nausea

Abdominal pain

Anorexia

Dry mouth

Vomiting

Dyspepsia

Ileus

Taste perversion

Hepatobiliary disorders

Increased hepatic enzymes

Biliary pain

Exacerbation of pancreatitis

Sphincter of Oddi dysfunction

Skin and subcutaneous tissue disorders

Rash

Urticaria

Renal and urinary disorders

Urinary retention

Ureteric spasm

Reproductive system and breast disorders

Amenorrhoea

Decreased libido

Erectile dysfunction

General disorders and administration site conditions

Asthenia

Fatigue

Malaise

Pruritus

Peripheral oedema

Drug withdrawal syndrome

Drug tolerance

Drug withdrawal (abstinence) syndrome neonatal

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Signs of morphine toxicity and overdose are pin-point pupils, skeletal muscle flaccidity, bradycardia, hypotension, respiratory depression, pneumonia aspiration, somnolence and central nervous system depression which can progress to stupor or coma. Death may occur from respiratory failure.

Circulatory failure and deepening coma may occur in more severe cases.

Overdose can result in death. Rhabdomyolysis progressing to renal failure has been reported in opioid overdose.

Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

Toxic leukoencephalopathy has been observed with morphine overdose.

Treatment of morphine overdose:

Primary attention should be given to the establishment of a patent airway and institution of assisted or controlled ventilation.

Oral activated charcoal (50g for adults, 1g/kg for children) may be considered if a substantial amount has been ingested within one hour, provided the airway can be protected.

The pure opioid antagonists are specific antidotes against the effects of opioid overdose. Other supportive measures should be employed as needed.

In the case of massive overdose, administer naloxone 0.8 mg intravenously. Repeat at 2-3 minute intervals as necessary, or by an infusion of 2 mg in 500 ml of normal saline or 5% dextrose (0.004 mg/ml).

The infusion should be run at a rate related to the previous bolus doses administered and should be in accordance with the patient's response. However, because the duration of action of naloxone is relatively short, the patient must be carefully monitored until spontaneous respiration is reliably re-established.

For less severe overdose, administer naloxone 0.2 mg intravenously followed by increments of 0.1 mg every 2 minutes if required.

Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to morphine overdose. Naloxone should be administered cautiously to persons who are known, or suspected, to be physically dependent on morphine. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome.

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • Vendal retardMorphini hydrochloridum · taken by mouth
  • MST ContinusMorphini sulfas · taken by mouth
  • SevredolMorphini sulfas · taken by mouth
  • OramorphMorphini sulfas · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Sevredol tablets 50mg. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →